Table 2 Impact of response dichotomy on the sample size required to achieve the target power by study duration. Target power is 80%. Lag duration is 1 month. Hazard ratio for responding patients is 0.3. Enrollment rate is 0.53 subjects/day
From: Treating non-responders: pitfalls and implications for cancer immunotherapy trial design
p (%) | Sample size required to achieve the target power | ||
|---|---|---|---|
Study duration | |||
3 years | 4 years | 5 years | |
20 | NA | 313 | 269 |
30 | 186 | 153 | 137 |
40 | 108 | 96 | 89 |
50 | 76 | 70 | 68 |
60 | 55 | 52 | 52 |